Immunome (IMNM) Return on Capital Employed (2020 - 2026)

Immunome has reported Return on Capital Employed for 7 years, with the latest figure at 38.27% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 4542.0% year-over-year to 38.27%; the trailing twelve-month figure through Mar 2026 stood at 38.27% (up 4542.0% YoY), and the FY2025 full-year result was 53.78%, up 16452.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 38.27%, up from 50.22% in the prior quarter.
• The five-year high for Return on Capital Employed was 38.27% in Q1 2026, with the low at 264.18% in Q1 2023.
• Historically, Return on Capital Employed has averaged 112.7% across 5 years, with a median of 104.0% in 2022.
• Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 18774 bps — and 2024, when it soared 14748 bps.
• Immunome's Return on Capital Employed stood at 184.83% in 2022, then jumped by 40 bps to 110.61% in 2023, then tumbled by 42 bps to 157.42% in 2024, then soared by 68 bps to 50.22% in 2025, then grew by 24 bps to 38.27% in 2026.
• The last three Return on Capital Employed figures came in at 38.27% (Q1 2026), 50.22% (Q4 2025), and 87.92% (Q3 2025), per Business Quant data.